Status:
ACTIVE_NOT_RECRUITING
Using rTMS to Treat Depression
Lead Sponsor:
Florida International University
Conditions:
Depression
Eligibility:
All Genders
18-80 years
Brief Summary
Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising, novel, non-invasive therapy for depression. In fact, there is an FDA-approved depression protocol to stimulate the dorsolateral pref...
Detailed Description
rTMS treatment for subjects who are suffering depression and are suitable for rTMS according to the inclusion and exclusion criteria using the FDA MagVenture: MagVita TMS system. This protocol will be...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Depression
- must be willing to cooperate.
Exclusion
- implanted electronic devices (e.g., pacemaker, medication pump, brain or vagus nerve stimulator, cochlear implant)
- history of seizures
- intracranial metal (e.g., aneurysm clip)
- inability of the participant to cooperate with the Transcranial Magnetic Stimulation (TMS) session
Key Trial Info
Start Date :
January 9 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 25 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05424224
Start Date
January 9 2023
End Date
September 25 2026
Last Update
October 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Florida International University
Miami, Florida, United States, 33174